Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Pembrolizumab In Combination With Anti platelet Therapy For Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
NCT Number:
NCT03245489
Phase:
I
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lip, Oral Cavity and Pharynx
Study Objectives:
To determine if anti-platelet therapy (acetylsalicylic acid, clopidogrel) combined with anti-PD-1 immunotherapy (pembrolizumab) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) is able to induce a more favorable immunologic response profile than immunotherapy alone.
Study Documents
(MUSC NetID required for document access)